A Phase 2 Pharmacodynamic Study of Pre-operative Figitumumab in Patients with Localized Prostate Cancer

Clinical Cancer Research, 05/03/2012

Figitumumab is biologically active in prostate cancer. PSA declines in treatment naive patients were observed, potentially mediated by insulin–like growth factor 1 receptor (IGF–IR) effects on androgen receptor expression. These results support the clinical relevance of IGF–IR signalling in prostate cancer and justify further clinical trials.

Print Article Summary Cat 2 CME Report